目的 探讨虎杖叶胶囊联合硝苯地平缓释片（Ⅱ）治疗肝阳上亢型原发性高血压的临床疗效。方法 选取2019年6月1日—2019年12月1日于南阳市中心医院心血管内科就诊的160例肝阳上亢型原发性高血压患者作为研究对象。将所有患者随机分为对照组和治疗组，每组各80例。对照组口服硝苯地平缓释片（Ⅱ），1片/次，2次/d；治疗组在对照组的基础上口服虎杖叶胶囊，2粒/次，2次/d。两组均治疗3个月。观察两组临床疗效，比较两组中医症候积分、收缩压和舒张压降低值、动脉脉搏传导速度、血清血管内皮细胞功能指标水平。结果 治疗后，与对照组（80.00%）相比，治疗组患者总有效率（92.50%）显著升高，差异具有统计学意义（P<0.05）。治疗后，两组患眩晕积分、头痛积分、急躁易怒积分均显著下降（P<0.05），且治疗组中医证候积分明显低于对照组，差异具有统计学意义（P<0.05）。治疗后，与对照组相比，治疗组收缩压和舒张压降低值均显著升高，差异具有统计学意义（P<0.05）。治疗后，两组颈-股动脉脉搏传导速度（cfPWV）、踝-肱动脉脉搏传导速度（baPWV）均显著降低，差异具有统计学意义（P<0.05），且治疗组cfPWV和baPWV明显低于对照组，差异具有统计学意义（P<0.05）。治疗后，两组患者内皮素（ET）水平显著降低，一氧化氮（NO）水平均显著升高（P<0.05），且治疗组ET水平降低更为明显，NO水平升高更加明显，差异具有统计学意义（P<0.05）。结论 虎杖叶胶囊联合硝苯地平缓释片治疗肝阳上亢型原发性高血压安全有效，可降低血压和中医症候积分，改善血管弹性水平，其降压机制可能与改善血管内皮细胞功能有关。

Objective To investigate the clinical efficacy of Huzhangye Capsules combined with Nifedipine Sustained-release Tablets (Ⅱ) in treatment of primary hypertension with liver Yang hyperactivity. Methods Patients (160 cases) with primary hypertension with liver Yang hyperactivity in the Department of Cardiovascular Disease of Nanyang Central Hospital from June 1, 2019 to December 1, 2019 were enrolled. All patients were randomly divided into control and treatment groups, and each group had 80 cases. Patients in the control group were po administered with Nifedipine Sustained-release Tablets (Ⅱ), 1 tablets/time, three times daily. Patients in the treatment group were po administered with Huzhangye Capsules on the basis of the control group, 2 grains/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the scores of TCM syndrome, the reduction of systolic and diastolic blood pressure, the arterial pulse conduction velocity, and the serum levels of vascular endothelial cell function indexes in two groups were compared. Results After treatment, compared with the control group (80.00%), the total effective rate of the treatment group (92.50%) was significantly increased, and the difference was statistically significant (P<0.05). After treatment, the vertigo score, headache score, irritability score of two groups were significantly decreased (P<0.05), and the score of TCM syndrome in the treatment group was significantly lower than that of the control group, and the difference was statistically significant (P<0.05). After treatment, compared with the control group, the decreased values of systolic and diastolic blood pressure in the treatment group were significantly increased, and the difference was statistically significant (P<0.05). After treatment, the levels of cfPWV and baPWV in two groups were significantly decreased (P<0.05), and the decrease of cfPWV and baPWV in the treatment group was significantly lower than that in the control group, the difference was statistically significant (P<0.05). After treatment, the level of ET in two groups were significantly decreased, but the level of NO were significantly increased (P<0.05), and the level of ET in the treatment group was significantly lower than that in the control group, while the level of NO in the treatment group was significantly higher than that in the control group, and the difference was statistically significant (P<0.05). Conclusion Huzhangye Capsules combined with Nifedipine Sustained-release Tablets (Ⅱ) is safe and effective in treatment of primary hypertension with liver Yang hyperactivity, which can reduce blood pressure and the score of TCM syndrome, and improve the level of vascular elasticity. Its antihypertensive mechanism may be related to improving the function of vascular endothelial cells.

R972